Measurable residual disease in AML: questions about the report
An MRD result in AML is a finding from a particular sample, method and treatment time point. “Not detected” means that the assay did not find measurable disease within its limits; it does not prove that every leukaemia cell has disappeared. A positive result also needs interpretation in the full clinical setting, rather than being used alone to choose the next treatment.
Start with what the laboratory measured
MRD stands for measurable residual disease; older documents may use “minimal residual disease”. Tests can look for an abnormal cell population or follow a suitable molecular marker. The report should identify the method and whether the sample came from blood or bone marrow. Those details matter when results from different laboratories seem to disagree.
Keep the entire report, including sensitivity, sample-quality comments and the laboratory interpretation. A screenshot showing a percentage without its heading is difficult to assess. If the report does not explain the units, ask the laboratory or treating team for clarification instead of converting the value yourself.
A result is meaningful at a defined point in treatment
Put the sample date next to the relevant treatment course. “After treatment” could mean after an initial cycle, after later consolidation or after transplantation. For a second opinion, specify which of those situations applies and attach the clinician’s assessment of remission from the same period.
Do not silently combine blood and marrow values into a single graph. Nor should results from different methods be presented as though they came from one continuous measuring scale. A simple table with the date, sample, method, result and treatment stage preserves the information that the haematologist needs to decide whether a comparison is valid.
What MRD can contribute to a decision
In AML, residual-disease assessment can add information to the disease’s genetic features and the response seen on routine examination. The clinical meaning also depends on test limitations, including sampling. This is why a specialist may request confirmation, further monitoring or a discussion of the treatment plan rather than give an automatic answer based on the word “positive”.
If a recommendation changes, ask for the link between the result and that change to be written clearly. Is the finding sufficiently established to act on? Would a repeat sample resolve a technical uncertainty, or is another type of assessment needed? What care continues while that question is settled? The answer should distinguish the medical decision from the administrative work of arranging a test.
Keep the original diagnosis available
Send the diagnostic marrow, flow-cytometry and molecular reports with the newer MRD results. A report labelled “genetic panel” may serve a different purpose from a follow-up assay. Ask the team which initial finding is being tracked and which part of the new report answers that question. Do not assume every detected variant has the same meaning for residual disease.
For a consultation abroad, preserve laboratory names, dates and original symbols in the translation. The guide to preparing a concise medical history can help present the clinical sequence. A useful request is: “Please explain whether these results are comparable and whether they change the next step.”
MRD testing does not replace assessment of a patient who becomes unwell. Symptoms should be reported through the existing treatment team’s urgent-care instructions, even if the latest MRD result was reassuring. Travel and a second opinion should be arranged around the current care plan, not used as reasons to delay it.
Sources
Medicina Turkey patient information. General guidance; individual medical decisions should be discussed with the treating clinician.